Sun Pharmaceutical Industries valuation

Share price at each year-end
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
Price multiples — at each FY-end close
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
34.86×————
5.05×————
7.04×————
47.86×————
Enterprise multiples
6.60×————
22.15×————
26.59×————
Yield
2.9%————
2.1%————
Reference — adjusted share basis
₹1,757.50————
₹50.41₹47.84₹45.55₹39.91₹35.32
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

SUNPHARMA₹1,757.50

Sun Pharmaceutical Industries Ltd.

· Pharma & Health
₹ CrorePeersCIPLADRREDDYLUPINAPOLLOHOSPMAXHEALTHDIVISLABTORNTPHARMZYDUSLIFEMcap ₹4.22L Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
Multiples — ₹ Crore base
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Price Multiples — at each FY-end close
P/E————34.86
P/B————5.05
P/Sales————7.04
Price to Free Cash Flow————47.86
Enterprise Multiples
EV/Sales————6.60
EV/EBITDA————22.15
EV/EBIT————26.59
Yield
Earnings Yield %————2.87
FCF Yield %————2.09
Reference — adjusted share basis
Price (FY-end close, adj.)————1,757.50
EPS (adj.)35.3239.9145.5547.8450.41
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 199%.